Hartford Investment Management Co. Reduces Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Hartford Investment Management Co. lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,364 shares of the medical equipment provider’s stock after selling 428 shares during the quarter. Hartford Investment Management Co.’s holdings in Hologic were worth $1,036,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HOLX. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the third quarter valued at $25,000. General Partner Inc. purchased a new position in Hologic in the 4th quarter valued at about $26,000. First Horizon Advisors Inc. grew its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. Cromwell Holdings LLC increased its position in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the last quarter. Finally, Covestor Ltd lifted its stake in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 0.6 %

NASDAQ:HOLX opened at $63.24 on Friday. The firm has a market capitalization of $14.19 billion, a P/E ratio of 19.95, a P/E/G ratio of 2.14 and a beta of 0.97. The business has a 50 day simple moving average of $71.04 and a 200 day simple moving average of $77.26. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 3.03. Hologic, Inc. has a 12-month low of $62.94 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.88% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on HOLX. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Evercore ISI dropped their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Morgan Stanley reduced their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Finally, Stephens restated an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.